NBIX
Neurocrine Biosciences Inc
Nasdaq · usd
Neurocrine Biosciences Inc (NBIX) trades at $159.76 (-3.79%) as of 6:28:42 PM EST on Nov 5, 2026, +11.35% over the past month. Market cap is $16.81B, with 4.5 days to cover in short interest.
Stock performance
How Neurocrine Biosciences Inc (NBIX) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.79%
- 1W
- +9.14%
- 1M
- +11.35%
- YTD
- +12.64%
- 1Y
- +3.20%
- 52-wk range
- $122.14 – $186.12
Key statistics
Today's trading snapshot for NBIX: day range, open, previous close, volume and market cap.
- Day range
- $159.50 – $167.68
- Open
- $167.68
- Prev close
- $166.05
- Volume
- 1.48M
- Market cap
- $16.81B
- Shares out
- 101.65M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Neurocrine Biosciences Inc: P/E, P/S, P/B, ROE and more.
- P/E
- 23.85
- P/S
- 4.53
- P/B
- 4.32
- P/FCF
- 16.12
- ROE
- 18.1%
- ROA
- 12.5%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 3, 2026
8-K filings
Material corporate events Neurocrine Biosciences Inc has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 2, 2026
On November 2, 2026, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2026.
- Executive officer appointmentSep 28, 2026
On September 28, 2026, the Board of Directors ... appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company's Chief Medical Officer, effective September 28, 2026.
- Merger completionMay 18, 2026
The Company completed the acquisition of Soleno on May 18, 2026, by causing Purchaser to merge with and into Soleno (the "Merger") pursuant to the Merger Agreement without any action by Soleno stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the "DGCL"). At the effective time of the Merger (the "Effective Time"), Purchaser was merged with and into Soleno, the separate existence of Purchaser ceased and Soleno continued as a direct wholly owned subsidiary of the Company.
- Investor presentationApr 6, 2026
On April 6, 2026, Neurocrine made available an investor presentation regarding the proposed transaction, a copy of which is attached as Exhibit 99.2 to this Report and incorporated by reference herein.
- Executive officer departureNov 24, 2025
Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (the "Company"), effective June 2, 2025.
NBIX short interest
How heavily NBIX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.5
- Short interest
- 6.45M
- Avg volume
- 1.42M
As of · reported to FINRA twice monthly.
NBIX news
The latest news and headlines about Neurocrine Biosciences Inc (NBIX).
- NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewpositiveZacks Investment Research· Nov 3, 2026
- Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesneutralZacks Investment Research· Nov 2, 2026
- Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to SaypositiveZacks Investment Research· Nov 2, 2026
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth StockpositiveZacks Investment Research· Oct 30, 2026
- Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?positiveZacks Investment Research· Oct 27, 2026
Frequently asked questions
What is the Neurocrine Biosciences Inc (NBIX) stock price today?
Neurocrine Biosciences Inc (NBIX) is trading at $159.76 (-3.79% on the day) as of 6:28:42 PM EST on Nov 5, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Neurocrine Biosciences Inc?
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders.
What is the short interest in NBIX?
As of Oct 15, 2026, NBIX has 6.45M shares short and 4.5 days to cover.
What exchange is NBIX listed on?
Neurocrine Biosciences Inc (NBIX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of NBIX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a NBIX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.